Get started
Author

Yung H. Chyung

Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis
2017 · Aleena Banerji, Paula Busse, et al. · New England Journal of Medicine · 178
PDF
Characterization of a Protein Complex Containing Spliceosomal Proteins SAPs 49, 130, 145, and 155
1999 · Biplab K. Das, Ling Xia, et al. · Molecular and Cellular Biology · 142
Ecallantide for the Acute Treatment of Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema: A Multicenter, Randomized, Controlled Trial
2014 · Lawrence M. Lewis, Charles Graffeo, et al. · Annals of Emergency Medicine · 67
PDF
A phase 1 study investigating DX-2930 in healthy subjects
2014 · Yung Chyung, Bradley Vince, et al. · Annals of Allergy Asthma & Immunology · 64
PDF
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study
2024 · Thomas O. Crawford, Basil T. Darras, et al. · Neurology · 61
PDF
Natural killer T cells are not the predominant T cell in asthma and likely modulate, not cause, asthma
2010 · Seddon Y. Thomas, Yung H. Chyung, et al. · Journal of Allergy and Clinical Immunology · 55
PDF
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
2021 · Doreen Barrett, Sanela Bilic, et al. · Advances in Therapy · 49
PDF
Characterization of Anaphylaxis After Ecallantide Treatment of Hereditary Angioedema Attacks
2014 · Timothy J. Craig, H. Henry Li, et al. · The Journal of Allergy and Clinical Immunology In Practice · 42
PDF
First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.
2021 · Timothy A. Yap, Minal A. Barve, et al. · Journal of Clinical Oncology · 7
Human Genetic Evidence to Inform Clinical Development of IL-6 Signaling Inhibition for Abdominal Aortic Aneurysm
2024 · Stephen Burgess, Héléne T. Cronjé, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 6
PDF
System for Simultaneous Tissue-Specific and Disease-Specific Regulation of Therapeutic Gene Expression
2003 · Yung H. Chyung, Peter D. Peng, et al. · Human Gene Therapy · 6
83PPhase 1 trial in healthy participants of KER-065, modified activin receptor ligand trap, support development in DMD and other neuromuscular disorders
2025 · H. Natarajan, M. Taimi, et al. · Neuromuscular Disorders · 3
532 First-in-human phase 1 trial of SRK-181: a latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors (DRAGON trial)
2021 · Timothy Yap, Minal Barve, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
P.126SRK-015, a fully human monoclonal antibody inhibiting myostatin activation, offers sustained target engagement across multiple species, including humans
2019 · A. Kalra, S. Cote, et al. · Neuromuscular Disorders · 3
Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (P15-5.005)
2022 · Thomas Crawford, Basil Darras, et al. · Neurology · 2
SMA - TREATMENT
2021 · A. Place, D. Barrett, et al. · Neuromuscular Disorders · 2
Modeling and Analyses to Identify Potential Dosing Regimens of DX-2930 for the Long-Term Prophylaxis of Hereditary Angioedema
2016 · H. James Wedner, Paula J. Busse, et al. · Journal of Allergy and Clinical Immunology · 2
PDF
Comparison Of Plasma Kallikrein Inhibition By The Endogenous C1-Inhibitor Versus DX-2930, a Monoclonal Antibody Inhibitor
2013 · Daniel J Sexton, Jon A Kenniston, et al. · Blood · 2
A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): A Study Update (1963)
2021 · Amy Place, Doreen Barrett, et al. · Neurology · 1
Relationship Between Drug Exposure and Clinical Response Observed in the Phase 1b Study of DX-2930 in Subjects with Hereditary Angioedema
2016 · Joshua S. Jacobs, Paula J. Busse, et al. · Journal of Allergy and Clinical Immunology · 1
PDF
Pharmacodynamic Effect of DX-2930 on Plasma Kallikrein in Hereditary Angioedema Patients
2016 · Mark A. Davis-Lorton, Paula J. Busse, et al. · Journal of Allergy and Clinical Immunology · 1
Refined Method for Collection of Plasma Samples to Evaluate the Role of Plasma Kallikrein in Various Disease States
2016 · Jonathan A. Bernstein, H. James Wedner, et al. · Journal of Allergy and Clinical Immunology · 1
Comparison Of Plasma Kallikrein Inhibition By The Monoclonal Antibody Inhibitor DX-2930 To Endogenous C1-INH
2014 · Daniel Sexton, Jon Kenniston, et al. · Journal of Allergy and Clinical Immunology · 1
PDF
Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease
2024 · Swati Debroy, Kristine Erickson, et al.
Relationship of pharmacokinetics and pharmacodynamics to apitegromab efficacy in patients with later-onset spinal muscular atrophy (Types 2 and 3 SMA): Results from the TOPAZ study
2021 · Thomas Crawford, Amy Place, et al. · Journal of the Neurological Sciences
Works count: 29
Citation count: 699
H-index: 8
I10-index: 8
Year
Topic
Type